MedTrace Logo

Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)

NCT00157950 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2016-02-04

Study results available
· View outcomes & findings →

Summary

This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.

Conditions

  • Papillomavirus Infections

Interventions

BIOLOGICAL

Gardasil™

Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)

BIOLOGICAL

Placebo

Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
23 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2006-06-30
Completion
2006-06-30

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00157950 on ClinicalTrials.gov